Iovance Biotherapeutics (NASDAQ: IOVA)
$3.50
(4.2%)
$0.14
Price as of April 25, 2025, 3:58 p.m. ET
Key Data Points
Current Price
$3.50
Daily Change
(4.2%) $0.14
Day's Range
$3.25 - $3.63
Previous Close
$3.51
Open
$3.32
Beta
1.33
Volume
14,760,425
Average Volume
9,765,053
Sector
Market Cap
$1B
Market Cap / Employee
$1M
52wk Range
$2.70 - $14.23
Revenue
$164M
Gross Margin
10.77%
Dividend Yield
N/A
EPS
-$1.30
CAPs Rating
-
Industry
Biotechnology
The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
Iovance Biotherapeutics Return vs. S&P
1 Year | 5 Year | 5 Year Annualized | Since IPO |
---|
Iovance Biotherapeutics Company Info
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
News & Analysis
The Fool has written over 100 articles on Iovance Biotherapeutics.
Featured Article
Iovance Biotherapeutics Stock Is Crashing. And Here's Why Things Could Get Even Worse This Year.
David Jagielski | Apr 23, 2025
Featured Article
This Biotech Stock Could Be the Best Investment of the Decade
There's an incredible growth story hiding in plain sight for investors who can look to the future.
James Brumley | Apr 18, 2025
Is Iovance Biotherapeutics a Millionaire-Maker?
Keith Speights | Apr 14, 2025
1 Stock Worth Buying Near Its 52-Week Low, According to Wall Street
Prosper Junior Bakiny | Mar 22, 2025
Down Nearly 80% From Its High, Is Iovance Biotherapeutics Stock Too Cheap to Pass Up?
David Jagielski | Mar 11, 2025
What's Wrong With Iovance Biotherapeutics Stock?
David Jagielski | Jan 30, 2025
Where Will Iovance Biotherapeutics Be in 5 Years?
Prosper Junior Bakiny | Jan 27, 2025
Meet the Growth Stock That Could Soar 280%, According to Wall Street Analysts
Cory Renauer | Jan 27, 2025
Financial Health
General
Q4 2024 | YoY Change |
---|
Revenue Growth Rate
Earnings Per Share Growth Rate
Assets
Q4 2024 | YoY Change |
---|
Liabilities
Q4 2024 | YoY Change |
---|
Ratios
Q4 2024 | YoY Change |
---|
Cash Flow
Q4 2024 | YoY Change |
---|
Valuation
Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | YoY Change |
---|
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.